Intravenous Alternative for Fidaxomicin in NPO Patients

Rationale for IV Alternative

For patients who cannot take oral medications (NPO status), alternative treatment strategies must be employed to treat Clostridioides difficile infection (CDI), as there is no intravenous formulation of fidaxomicin available for clinical use 1, 2, 3
Unlike oral administration, intravenous vancomycin alone is ineffective for CDI as it is not excreted into the colon 3, 4

The recommended alternative regimen for patients who are NPO and cannot take oral fidaxomicin is intravenous vancomycin 500mg every 8 hours plus vancomycin retention enema 250-500mg in 100-500mL saline 4 times daily for 10 days 1, 2, 3
Vancomycin enema dosing: 250-500mg in 100-500mL saline administered 2-4 times daily via rectal tube or catheter 3, 4
Duration of therapy: 10 days (standard duration for CDI treatment) 1

Vancomycin enema is an effective therapy for patients who cannot tolerate oral preparations or have ileus with delayed passage of oral medications 3
Trans-stoma vancomycin may be effective in surgical patients with Hartmann resection, ileostomy, or colon diversion 3
A retrospective review showed 70% of patients with severe C. difficile colitis responded to intracolonic vancomycin with complete resolution without surgery 3

For severe or fulminant CDI, higher doses of vancomycin enema (up to 1 gram 2-4 times daily) may be considered 1, 3
Patients with ileus or toxic megacolon require more aggressive management with combination therapy 2, 3
Early surgical evaluation should be considered for patients failing maximal medical therapy including intracolonic vancomycin enemas 3

Once the patient can tolerate oral medications, transition to oral fidaxomicin 200mg twice daily to complete the 10-day course 1, 2
Alternatively, oral vancomycin 125mg four times daily can be used to complete the course 1, 2

Monitor for clinical improvement in diarrhea and other signs of infection 5
Response may require 3-5 days after starting therapy 5
"Test of cure" is not recommended after CDI treatment 6
Be vigilant for treatment failure, which is more common in older, frail patients with hypoalbuminemia (albumin <2.5 g/dL) 3

The Infectious Diseases Society of America recommends vancomycin (125 mg orally four times daily for 10 days) or fidaxomicin (200 mg orally twice daily for 10 days) as first-line therapy for initial episodes of CDI, over metronidazole 7, 8
For non-severe CDI, fidaxomicin 200 mg orally twice daily for 10 days is a preferred treatment 8
For non-severe CDI, vancomycin 125 mg orally four times daily for 10 days is an alternative treatment 7, 8
Discontinuing the inciting antibiotic agent(s) as soon as possible is recommended for CDI treatment 7

For first recurrence of CDI, if metronidazole was used for the initial episode, vancomycin 125 mg orally four times daily for 10 days is recommended 9, 10
For second or subsequent recurrence of CDI, vancomycin in a tapered and pulsed regimen, or vancomycin followed by rifaximin, or fidaxomicin 200 mg twice daily for 10 days are treatment options 10, 11
Fecal microbiota transplantation (FMT) is recommended after at least 2 recurrences of CDI have failed appropriate antibiotic treatments 10, 11, 8

For pediatric patients with non-severe initial episode or first recurrence of CDI, either metronidazole or vancomycin for 10 days is recommended 10, 11
For pediatric patients with severe or fulminant CDI, vancomycin with or without IV metronidazole is recommended 10, 11

The standard duration of CDI therapy is 10 days, but consider extending to 14 days if response is delayed, particularly with metronidazole 7, 8
Empiric therapy should be considered when substantial delay in laboratory confirmation is expected or for fulminant CDI 7
Repeated metronidazole courses should be avoided due to risk of cumulative and potentially irreversible neurotoxicity 7

Inadequate follow-up, as "test of cure" is not recommended after CDI treatment 12
Failure to discontinue inciting antibiotics, which may influence the risk of CDI recurrence 7
Underestimating recurrence risk, as approximately 20% of patients experience recurrence, with higher risk in elderly patients and those with continued antibiotic use 12